Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. Its primary product candidates include ORIC-114 (EGFR/HER2 exon 20 inhibitor), ORIC-944 (PRC2 allosteric inhibitor), and ORIC-533 (CD73 inhibitor). The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(34,566) | $(25,478) | $(91,540) | $(72,367) |
| Net Loss Per Share (Basic/Diluted) | $(0.49) | $(0.44) | $(1.32) | $(1.46) |
| Total Operating Expenses | $38,318 | $28,682 | $103,325 | $79,352 |
| Research & Development (R&D) | $31,202 | $22,388 | $82,102 | $60,691 |
| General & Administrative (G&A) | $7,116 | $6,294 | $21,223 | $18,661 |
| Cash, Cash Equivalents & Investments | $272,369 | $208,187 | $272,369 | $208,187 |
| Accumulated Deficit | $(526,467) | $(406,597) | $(526,467) | $(406,597) |
Note: Cash, Cash Equivalents & Investments combines Cash ($44,230), Short-term investments ($228,139), and Long-term investments ($9,998) as of Sept 30, 2024.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended September 30, 2024, increased by $19.2 million (26%) compared to the same period in 2023, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose $21.4 million (35%) year-over-year for the nine-month period. This was driven by a $16.5 million increase in external costs related to the advancement of ORIC-114 and ORIC-944, and a $4.9 million increase in internal personnel costs.
- Liquidity Position: Total cash, cash equivalents, and investments increased to $272.4 million as of September 30, 2024, from $208.2 million at September 30, 2023. This increase was primarily due to a private placement of common stock in January 2024 yielding $125.0 million in gross proceeds.
- Stock-Based Compensation: Total stock-based compensation expense increased to $15.0 million for the nine months ended September 30, 2024, from $11.3 million in the prior year period.
Guidance, Outlook, and Risks
- Capital Runway: Management believes current cash, cash equivalents, and investments are sufficient to fund operations into late 2026.
- Clinical Progress:
- ORIC-114: Phase 1b dose expansion cohorts initiated for NSCLC patients; updated data expected in the first half of 2025.
- ORIC-944: Dosing initiated in combination with darolutamide and apalutamide in metastatic prostate cancer trials. Collaborations with Bayer and Johnson & Johnson established for these combination studies.
- ORIC-533: Completing Phase 1b trial in multiple myeloma; evaluating strategic partnerships for combination therapies.
- Financing: The company maintains an "at-the-market" (ATM) sales agreement to sell up to $200 million of common stock. It recently completed a private placement in January 2024.
- Key Risks:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to advance clinical trials and commercialize products.
- Clinical Uncertainty: No assurance that product candidates will demonstrate safety and efficacy or receive regulatory approval.
- Third-Party Dependence: Reliance on third-party manufacturers for drug supply and CROs for clinical trials.
- Legal Proceedings: The company's Chief Business Officer was found liable for insider trading in a matter unrelated to Oric; the officer is permanently enjoined from violating securities laws but is not prohibited from serving as an officer.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the "late 2026" runway given the accelerating R&D spend ($82.1M for 9 months YTD).
- ORIC-114 Data Readout: Monitor the timing and results of the Phase 1b data update expected in the first half of 2025.
- Collaboration Terms: Review the specific financial terms and milestone obligations associated with the new Bayer and Johnson & Johnson collaborations for ORIC-944.
- Manufacturing Supply Chain: Assess the risks associated with reliance on single-source third-party manufacturers for all clinical product candidates.
- Legal Status of CBO: Confirm the current status of the Chief Business Officer's appeal regarding the SEC insider trading judgment and any potential impact on company operations or reputation.